Evidence map›Paper›PMID 36746936›Full record

ArticleCell death & disease2023

Regulation of immunological tolerance by the p53-inhibitor iASPP.

Elliot H Akama-Garren, Paul Miller, Thomas M Carroll, Michael Tellier, Gopinath Sutendra, Ludovico Buti, Justyna Zaborowska, Robert D Goldin, Elizabeth Slee, Francis G Szele and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Elliot H Akama-GarrenLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK. elliot_akama-garren@hms.harvard.edu.ORCID 0000-0002-1690-2055
Paul MillerLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0002-5800-1220
Thomas M CarrollLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Michael TellierSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.ORCID 0000-0002-4130-9050
Gopinath SutendraLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Ludovico ButiLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Justyna ZaborowskaSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.
Robert D GoldinCentre for Pathology, St. Mary's Hospital, Imperial College, London, W2 1NY, UK.ORCID 0000-0001-5184-4519
Elizabeth SleeLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Francis G SzeleDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3PT, UK.ORCID 0000-0002-2931-0673
Shona MurphySir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.
Xin LuLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK. xin.lu@ludwig.ox.ac.uk.
University of Oxford · GBCharles River Laboratories (Netherlands) · NLHarvard University · USSt Mary's Hospital · GBUniversity of Alberta · CA

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
TRAINING IN TRANSPLANTATION BIOLOGYT32AI007529 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 1998 to 2024
$6.4M
Follicular helper T cells as drivers of epitope spreadingF30AI160909 · NIAID · HARVARD MEDICAL SCHOOL · PI AKAMA-GARREN, ELLIOT HIDEKI · 2021 to 2023
$125k
NIAID NIH HHS F30 AI160909NIAID NIH HHS T32 AI007529NIGMS NIH HHS T32 GM007753Wellcome TrustWellcome Trust WT106134AIAWellcome Trust WT210641/Z/18/Z
6 · The paper itself

Abstract

Maintenance of immunological homeostasis between tolerance and autoimmunity is essential for the prevention of human diseases ranging from autoimmune disease to cancer. Accumulating evidence suggests that p53 can mitigate phagocytosis-induced adjuvanticity thereby promoting immunological tolerance following programmed cell death. Here we identify Inhibitor of Apoptosis Stimulating p53 Protein (iASPP), a negative regulator of p53 transcriptional activity, as a regulator of immunological tolerance. iASPP-deficiency promoted lung adenocarcinoma and pancreatic cancer tumorigenesis, while iASPP-deficient mice were less susceptible to autoimmune disease. Immune responses to iASPP-deficient tumors exhibited hallmarks of immunosuppression, including activated regulatory T cells and exhausted CD8

Indexed as

Autoimmune DiseasesNeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansInhibitor of Apoptosis ProteinsIntracellular Signaling Peptides and ProteinsMiceRepressor ProteinsTumor Suppressor Protein p53Inhibitor of Apoptosis ProteinsIntracellular Signaling Peptides and ProteinsRepressor ProteinsTumor Suppressor Protein p53

Identifiers

PMID36746936
PMCPMC9902554
OpenAlexW4319320751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.